Skip to main content
. 2020 Jun 4;4(2):021502. doi: 10.1063/1.5132618

FIG. 1.

FIG. 1.

The four components of the comprehensive in vitro proarrhythmia assay. (1) Assessment of drug effects on multiple ion currents. (2) In silico prediction of cardiac action potential. (3) In vitro effects on human stem cell derived cardiac myocytes. (4) Human ECG in phase I clinical trials. Reproduced with permission from Vicente et al., Clin. Pharmacol. Ther. 103(1), 54–66 (2018) Copyright 2018 Authors, licensed under a Creative Commons Attribution Non-Commercial License.